Drug Trial Radar · NCT01709318
A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
Last checked: Nov 20, 2026Latest source record: May 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
666
Actual
Start
Dec 12, 2012
Primary completion
Oct 22, 2013
Study completion Oct 22, 2013
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this trial was to identify at least one next generation ring (NGR) that demonstrates inhibition of ovulation (which was considered confirmed if in the subset of participants ovulation was observed in less than 15% of the participants at any time during the 3 treatment cycles of the study) and cycle control that was non-inferior to NuvaRing®, as judged by the incidence of breakthrough bleeding and/or spotting (BTB-S) during Cycle 3. The primary hypothesis was that at least 1 of the 6 NGRs would show inhibition of ovulation and cycle control during Treatment Cycle 3 that is non-inferior to NuvaRing®, as judged by the incidence of BTB-S.
Conditions
- Contraception
Interventions
Nomegestrol acetate (NOMAC)Drug
Daily release of 500, 700, or 900 μg.
Etonogestrel (ENG)Drug
Daily release of 75, 100, 120 or 125 μg
Ethinyl estradiol (EE)Drug
Daily release of 15 μg
Estradiol (E2)Drug
Daily release of 300 μg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Ovulation Incidence, by CycleTime frame: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)
- Percentage of Participants With Progesterone Concentrations >16 Nmol/L, by CycleTime frame: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)
- Percentage of Participants With Breakthrough Bleeding and/or Spotting During Cycle 3Time frame: Day 1 Cycle 3 through Day 28 Cycle 3 (Up to ~28 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.